Monroe Bank & Trust’s Biogen BIIB Stock Holding History

Monroe Bank & Trust’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-10	Closed	-$3K	–	143
2016 Q1	$3K	Buy	+10	New	+$2.64K	﹤0.01%	342

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Monroe Bank & Trust's BIIB Position: Q2 2016 in Review

Monroe Bank & Trust sold out of Biogen (BIIB) in Q2 2016, closing a stake of 10 shares — an estimated $3K sold.

Monroe Bank & Trust first reported a position in BIIB in Q1 2016 and held it in 1 quarter. The position peaked at $3K in Q1 2016. 965 funds tracked by Wall St. Rank hold BIIB as of Q2 2016.

Monroe Bank & Trust reported no remaining Biogen position as of Q2 2016 after selling out during the quarter.
Monroe Bank & Trust sold 10 Biogen shares in Q2 2016, an estimated $3K.
Monroe Bank & Trust first reported a position in Biogen in Q1 2016 and held it in 1 quarter.
Monroe Bank & Trust's Biogen position peaked at $3K in Q1 2016.
965 funds tracked by Wall St. Rank held Biogen as of Q2 2016.

Based on Monroe Bank & Trust's 13F filing for Q2 2016, filed 10 Aug 2016.